On September 12, 2023 Kane Biotech Inc has closed the transaction.All securities issued in connection with the Offering are subject to a hold period of four-months and one day in Canada.The closing of the Offering remains subject to the final approval of the TSX Venture Exchange.The transaction involved participation from President and Chief Executive Officer, Marc Edwards, and Chief Financial Officer, Raymond Dupuis participated in the Offering (the ?Insider Subscription?).The transaction included participation from 15 placees with two existing insider involvement for 250,000 shares.